Evidence map›Paper›PMID 28739267›Full record

Observational studyJournal of diabetes and its complications2017

H. pylori seroprevalence and risk of diabetes: An ancillary case-control study nested in the diabetes prevention program.

Saud Alzahrani, Jason Nelson, Steven F Moss, Jessica K Paulus, William C Knowler, Anastassios G Pittas, Diabetes Prevention Program Research Group

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Journal of diabetes and its complications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Children (Basel, Switzerland) · 2022
    Review
  5. Article
  6. Article
  7. World journal of gastroenterology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Saud AlzahraniDivision of Endocrinology, Diabetes and Metabolism, Tufts Medical Center, Boston, MA; Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia. Electronic address: dr_alzahrani_s@yahoo.com.
Jason NelsonPredictive Analytics and Comparative Effectiveness (PACE) Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA.
Steven F MossDivision of Gastroenterology, Brown University, Providence, RI.
Jessica K PaulusPredictive Analytics and Comparative Effectiveness (PACE) Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA.
William C KnowlerNational Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, AZ.
Anastassios G PittasDivision of Endocrinology, Diabetes and Metabolism, Tufts Medical Center, Boston, MA; Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Diabetes Prevention Program Research Group
Tufts Medical Center · USBrown University · USNational Institute of Diabetes and Digestive and Kidney Diseases · US

Funding

PRIMARY PREVENTION TRIAL--DATA COORDINATING CENTERU01DK048489 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI JABLONSKI, KATHLEEN ANN, TEMPROSA, MARINELLA · 1994 to 2021
$84.8M
Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Sakeneh Zraika · 1986 to 2026
$41.4M
TUFTS CLINICAL AND TRANSLATION SCIENCE INSTITUTE (UL1): BPCAUL1RR025752 · NCRR · TUFTS UNIVERSITY BOSTON · PI SELKER, HARRY P. · 2008 to 2011
$17.6M
Post-DDP Follow-up StudyU01DK048413 · NIDDK · UNIVERSITY OF WASHINGTON · PI KAHN, STEVEN EMANUEL · 1994 to 2021
$13.7M
PRIMARY PREVENTION TRIAL (DPT-2)U01DK048397 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI NATHAN, DAVID M · 1994 to 2021
$12.0M
NIDDM PRIMARY PREVENTION TRIAL (DPT 2)U01DK048404 · NIDDK · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · PI LAFERRERE, BLANDINE B · 1994 to 2021
$11.6M
PRIMARY PREVENTION TRIAL (DPT-2)U01DK048339 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ARANETA, MARIA ROSARIO GORREZ, MUDALIAR, SUNDER · 1994 to 2022
$11.4M
NIDDM PRIMARY PREVENTION TRIALU01DK048412 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VENDITTI, ELIZABETH MARY · 1994 to 2021
$11.4M
PRIMARY PREVENTION TRIALU01DK048443 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI WATSON, KAROL E · 1994 to 2021
$10.2M
Post-DPP Follow-up StudyU01DK048375 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI DABELEA, DANA · 1994 to 2022
$10.0M
PRIMARY PREVENTION TRIAL (DPT-2)U01DK048380 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WALLIA, AMISHA · 1994 to 2021
$9.2M
POST-DPP FOLLOW-UP STUDYU01DK048514 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HAZUDA, HELEN P. · 1994 to 2021
$9.1M
NCRR NIH HHS UL1 RR025752NIDDK NIH HHS P30 DK017047NIDDK NIH HHS R01 DK076092NIDDK NIH HHS R01 DK079003NIDDK NIH HHS U01 DK048339NIDDK NIH HHS U01 DK048375NIDDK NIH HHS U01 DK048380NIDDK NIH HHS U01 DK048397NIDDK NIH HHS U01 DK048400NIDDK NIH HHS U01 DK048404NIDDK NIH HHS U01 DK048407NIDDK NIH HHS U01 DK048412NIDDK NIH HHS U01 DK048413NIDDK NIH HHS U01 DK048437NIDDK NIH HHS U01 DK048443NIDDK NIH HHS U01 DK048485NIDDK NIH HHS U01 DK048489NIDDK NIH HHS U01 DK048514
6 · The paper itself

Abstract

objectiveTo determine the association between H. pylori infection and risk of incident diabetes in adults at high risk for diabetes who participated in the Diabetes Prevention Program (DPP) study.

methodsIn a nested case-control study conducted among 421 adults with newly diagnosed diabetes and 421 matched controls, we examined the association between serological status of H. pylori at baseline and risk of incident diabetes over a mean follow-up period of 2.6years. Using data from the baseline visit of the DPP, we also examined the cross-sectional association between presence of H. pylori antibodies and insulin sensitivity, insulin secretion and the disposition index-like measure after a 75-g oral glucose tolerance test (OGTT).

resultsAt baseline, H. pylori antibodies were present in 40% of participants who developed diabetes and 39% of controls. After adjusting for matching factors, there was no association between exposure to H. pylori and incident diabetes (odds ratio [OR] of 1.04 (95% CI, 0.77 to 1.40). In cross-sectional analyses, H. pylori status was not significantly associated with insulin sensitivity and disposition index-like measure from OGTT.

conclusionsIn adults at high risk for diabetes, H. pylori seropositivity was not associated with risk of developing diabetes.

Indexed as

AdultAntibodies, BacterialCase-Control StudiesCohort StudiesCross-Sectional StudiesDiabetes Mellitus, Type 2FemaleHelicobacter InfectionsHelicobacter pyloriHumansIncidenceInsulin ResistanceLongitudinal StudiesMaleMiddle AgedPrevalenceAntibodies, BacterialCase–controlDiabetes mellitusDiabetes prevention programH. pyloriMetabolic syndromeObservational study

Identifiers

PMID28739267
PMCPMC5603174
OpenAlexW2621312431

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.